Meeder Asset Management Inc. Purchases 16,682 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Meeder Asset Management Inc. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4,212.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,078 shares of the biopharmaceutical company’s stock after buying an additional 16,682 shares during the quarter. Meeder Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,080,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sei Investments Co. boosted its stake in Regeneron Pharmaceuticals by 31.6% in the third quarter. Sei Investments Co. now owns 32,000 shares of the biopharmaceutical company’s stock valued at $18,033,000 after acquiring an additional 7,676 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Regeneron Pharmaceuticals by 218.1% in the third quarter. Mercer Global Advisors Inc. ADV now owns 2,564 shares of the biopharmaceutical company’s stock worth $1,435,000 after buying an additional 1,758 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $505,000. Private Trust Co. NA boosted its position in shares of Regeneron Pharmaceuticals by 48.9% during the 4th quarter. Private Trust Co. NA now owns 819 shares of the biopharmaceutical company’s stock valued at $395,000 after acquiring an additional 269 shares during the last quarter. Finally, Carroll Financial Associates Inc. raised its position in shares of Regeneron Pharmaceuticals by 159.6% during the 4th quarter. Carroll Financial Associates Inc. now owns 135 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 83 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Several research firms have recently commented on REGN. Cowen decreased their price objective on Regeneron Pharmaceuticals from $684.00 to $565.00 and set an “outperform” rating on the stock in a report on Monday, February 8th. Credit Suisse Group upped their price target on Regeneron Pharmaceuticals from $753.00 to $760.00 and gave the stock an “outperform” rating in a research note on Monday, March 1st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $590.00 price target on the stock in a report on Wednesday, January 13th. Morgan Stanley lowered their price target on Regeneron Pharmaceuticals from $525.00 to $477.00 and set an “equal weight” rating on the stock in a report on Monday, April 26th. Finally, SVB Leerink upped their target price on shares of Regeneron Pharmaceuticals from $655.00 to $657.00 and gave the company an “outperform” rating in a report on Thursday, April 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $644.17.

NASDAQ:REGN traded down $6.32 during mid-day trading on Tuesday, reaching $482.30. The company’s stock had a trading volume of 15,705 shares, compared to its average volume of 980,126. The company has a quick ratio of 3.12, a current ratio of 3.89 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $51.67 billion, a PE ratio of 17.61, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. The stock has a fifty day moving average of $482.38 and a 200-day moving average of $503.31. Regeneron Pharmaceuticals, Inc. has a 1 year low of $441.00 and a 1 year high of $664.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $7.11 by $2.42. Regeneron Pharmaceuticals had a net margin of 38.28% and a return on equity of 28.97%. The company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.40 billion. During the same period last year, the company posted $7.50 earnings per share. Regeneron Pharmaceuticals’s revenue was up 11.7% compared to the same quarter last year. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 27.23 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Portfolio Manager

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.